Emcitate (Emtricitabine)

What Is Emcitate and What Is It Used For?

Quick Answer: Emcitate contains emtricitabine, an antiviral medicine belonging to the nucleoside reverse transcriptase inhibitor (NRTI) class. It is used in combination with other antiretrovirals to treat HIV-1 infection in adults and children, and as part of pre-exposure prophylaxis (PrEP) to prevent HIV transmission.

Emcitate is a branded generic formulation of emtricitabine (also known as FTC), manufactured by Cipla Ltd. The originator product is Emtriva, developed by Gilead Sciences. Emtricitabine is a synthetic nucleoside analogue of cytidine that has become one of the most commonly prescribed antiretroviral medications worldwide, forming the backbone of many modern HIV treatment and prevention regimens.

Emtricitabine works by interfering with the activity of HIV-1 reverse transcriptase, an enzyme that the virus requires to convert its RNA genome into DNA within infected host cells. After being taken up by cells and phosphorylated to its active triphosphate form, emtricitabine competes with the natural substrate deoxycytidine 5'-triphosphate. When incorporated into the growing viral DNA chain, it causes chain termination, effectively halting viral replication.

The primary indications for emtricitabine include:

• Treatment of HIV-1 infection: Always used in combination with at least two other antiretroviral agents as part of a complete regimen. Emtricitabine is a preferred NRTI backbone component recommended by WHO, BHIVA (British HIV Association), EACS (European AIDS Clinical Society), and DHHS (US Department of Health and Human Services) guidelines.
• Pre-exposure prophylaxis (PrEP): In combination with tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF), emtricitabine is approved for daily use in HIV-negative individuals at substantial risk of acquiring HIV-1 infection. Clinical trials including iPrEx and PROUD demonstrated significant reductions in HIV acquisition with adherent PrEP use.
• Hepatitis B activity: Emtricitabine has antiviral activity against hepatitis B virus (HBV), although it is not typically prescribed solely for this purpose. This dual activity is clinically important in HIV/HBV co-infected patients.

Emtricitabine is also available in numerous fixed-dose combination products, including Truvada (emtricitabine/tenofovir DF), Descovy (emtricitabine/tenofovir AF), Atripla, Biktarvy, Genvoya, Odefsey, Complera, and Symtuza. These single-tablet regimens have simplified HIV treatment by reducing pill burden and improving adherence.

What Should You Know Before Taking Emcitate?

Quick Answer: Before starting emtricitabine, you should be tested for hepatitis B virus (HBV) co-infection, have your kidney function assessed, and inform your doctor about all other medications you are taking. Emtricitabine must not be combined with lamivudine.

Contraindications

Emtricitabine is contraindicated in patients with known hypersensitivity to emtricitabine or any of the excipients in the formulation. Additionally, emtricitabine must not be co-administered with lamivudine (3TC), as both drugs are cytidine analogues that compete for the same intracellular phosphorylation pathway. Co-administration provides no additional antiviral benefit and may increase the risk of resistance mutations and adverse effects.

Warnings and Precautions

Several important warnings apply to the use of emtricitabine:

• Hepatitis B virus (HBV) co-infection: All patients should be tested for HBV before initiating emtricitabine. Discontinuation of emtricitabine in HBV co-infected patients can cause severe, potentially life-threatening hepatitis B flares with rapid increases in HBV DNA and liver enzymes. Hepatic function should be monitored closely for at least several months after stopping therapy. In some cases, initiation of anti-hepatitis B treatment may be warranted.
• Renal impairment: Emtricitabine is primarily eliminated by the kidneys through both glomerular filtration and active tubular secretion. Dose adjustment is required in patients with creatinine clearance (CrCl) below 50 mL/min. Renal function should be monitored regularly during treatment.
• Lactic acidosis and hepatomegaly: As a nucleoside analogue, emtricitabine carries a class warning for lactic acidosis and severe hepatomegaly with steatosis, including fatal cases. Treatment should be suspended if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop. Risk factors include female sex, obesity, and prolonged NRTI use.
• Immune reconstitution inflammatory syndrome (IRIS): In patients with severe immune deficiency at the time of starting antiretroviral therapy, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise, requiring clinical evaluation and treatment.
• Fat redistribution: Combination antiretroviral therapy has been associated with body fat redistribution (lipodystrophy) in some patients, including loss of peripheral subcutaneous fat and accumulation of central/visceral fat.

Pregnancy and Breastfeeding

Emtricitabine is generally considered safe during pregnancy and is included in many recommended first-line regimens for pregnant women living with HIV, as endorsed by WHO, BHIVA, and DHHS guidelines. Extensive data from the Antiretroviral Pregnancy Registry and clinical trials have not demonstrated an increased risk of birth defects associated with first-trimester exposure to emtricitabine.

Emtricitabine is excreted in human breast milk. However, breastfeeding is not recommended for HIV-positive mothers regardless of antiretroviral treatment status or viral suppression level, due to the risk of postnatal HIV transmission through breast milk. In resource-limited settings where the risk of infant mortality from infectious diseases and malnutrition may outweigh the risk of HIV transmission, WHO provides specific guidance on breastfeeding in the context of maternal antiretroviral therapy.

How Does Emcitate Interact with Other Drugs?

Quick Answer: Emtricitabine has a relatively clean drug interaction profile because it is not metabolized by the CYP450 enzyme system. The most important interaction is with lamivudine, which is contraindicated. Nephrotoxic drugs may increase emtricitabine plasma levels by reducing renal clearance.

One of the advantages of emtricitabine in antiretroviral therapy is its minimal potential for drug-drug interactions. Unlike protease inhibitors and non-nucleoside reverse transcriptase inhibitors (NNRTIs), emtricitabine is not a substrate, inhibitor, or inducer of cytochrome P450 (CYP450) enzymes. This means it does not significantly affect the metabolism of most concomitant medications and is not affected by CYP450 inhibitors or inducers.

Emtricitabine is primarily eliminated unchanged by the kidneys. Therefore, drugs that affect renal function or compete for active tubular secretion may alter emtricitabine plasma concentrations. The following table summarizes the most clinically relevant drug interactions:

Major Interactions

Minor Interactions and Precautions

Notably, emtricitabine does not interact significantly with protease inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs), statins, antihypertensives, oral contraceptives, antidepressants, or most other commonly prescribed medications. This favorable interaction profile makes emtricitabine a versatile component in diverse antiretroviral regimens.

What Is the Correct Dosage of Emcitate?

Quick Answer: The standard adult dose of emtricitabine is 200 mg once daily (capsule) or 240 mg once daily (oral solution). Dose adjustment is required for patients with reduced kidney function (CrCl below 50 mL/min). Children are dosed based on body weight.

Adults

For adults and adolescents weighing 33 kg or more with normal kidney function (creatinine clearance 50 mL/min or greater), the recommended dose is:

Children

Pediatric dosing is based on age and body weight. Emtricitabine oral solution is available for children who cannot swallow capsules:

Elderly

There is no specific age-related dose adjustment for emtricitabine beyond renal function-based adjustments. However, elderly patients are more likely to have reduced kidney function, so creatinine clearance should be assessed before and during treatment. Use the renal impairment dosing guidelines below as appropriate.

Renal Impairment Dosing

Missed Dose

If you miss a dose of emtricitabine, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. Consistent adherence to your antiretroviral regimen is crucial for maintaining viral suppression and preventing the development of drug-resistant HIV.

Overdose

There is limited clinical experience with emtricitabine overdose. In cases of overdose, standard supportive measures should be applied, including monitoring of vital signs and observation of the patient's clinical status. Emtricitabine can be partially removed by hemodialysis (approximately 30% of the dose is removed over a 3-hour dialysis session). If overdose is suspected, contact your local poison control center or emergency services immediately.

What Are the Side Effects of Emcitate?

Quick Answer: The most common side effects of emtricitabine include headache, nausea, diarrhea, and elevated creatine kinase (very common). Skin hyperpigmentation, particularly on palms and soles, is a distinctive side effect more frequently seen in darker-skinned patients. Rare but serious effects include lactic acidosis and severe hepatitis B flares upon discontinuation.

Emtricitabine is generally well tolerated, and most side effects are mild to moderate in severity. Many adverse effects improve or resolve with continued treatment as the body adjusts to the medication. It is important to distinguish side effects of emtricitabine from those caused by other components of the antiretroviral regimen, as emtricitabine is always used in combination therapy.

The following side effect frequency classification is based on clinical trial data and post-marketing surveillance as reported in the EMA Summary of Product Characteristics (SmPC) and FDA prescribing information:

Skin hyperpigmentation deserves special mention as a distinctive side effect of emtricitabine. It manifests as discoloration of the skin, most commonly on the palms of the hands and soles of the feet, and is more frequently observed in patients with darker skin tones. This effect is generally mild, cosmetic in nature, and does not require discontinuation of treatment. The mechanism is believed to involve melanocyte stimulation, though the exact pathway is not fully understood.

How Should You Store Emcitate?

Quick Answer: Store emtricitabine capsules at room temperature (15–30°C / 59–86°F) in the original container. The oral solution should be refrigerated (2–8°C), but can be stored at room temperature for up to 3 months if dispensed to the patient. Keep out of reach of children.

Proper storage of emtricitabine is essential to ensure the medication remains effective and safe throughout its shelf life. Incorrect storage conditions can lead to degradation of the active ingredient, potentially reducing the drug's potency and therapeutic effectiveness.

• Capsules: Store at 15–30°C (59–86°F). Keep in the original container with the cap tightly closed. Protect from excessive heat and moisture. Do not store in the bathroom or near a kitchen sink.
• Oral solution: Store refrigerated at 2–8°C (36–46°F). If dispensed to the patient, the solution may be stored at room temperature (up to 25°C / 77°F) for a maximum of 3 months. Do not freeze.
• Shelf life: Capsules typically have a shelf life of 36 months from the date of manufacture. The oral solution should be used within the specified timeframe on the label, or within 3 months if stored at room temperature.
• Disposal: Do not flush unused medication down the toilet or pour it into drains. Return unused or expired medicines to your pharmacist or use an approved medication take-back program.

Keep all medicines out of the sight and reach of children. Store emtricitabine separately from other medications to avoid accidental mix-ups. If the capsules appear discolored, damaged, or if the oral solution has changed in appearance, do not use the medication and consult your pharmacist.

What Does Emcitate Contain?

Quick Answer: Each Emcitate capsule contains 200 mg of emtricitabine as the active ingredient. The oral solution contains 10 mg/mL of emtricitabine. Inactive ingredients vary by formulation and include excipients such as microcrystalline cellulose, crospovidone, magnesium stearate, and gelatin (capsule shell).

Active Ingredient

• Emtricitabine — 200 mg per hard capsule; 10 mg/mL in oral solution

Inactive Ingredients — Capsules

The capsule formulation typically contains the following excipients (specific formulation may vary by manufacturer):

• Microcrystalline cellulose
• Crospovidone
• Povidone
• Magnesium stearate
• Capsule shell: Gelatin, titanium dioxide, FD&C Blue No. 2, iron oxide (printing ink)

Inactive Ingredients — Oral Solution

The oral solution formulation typically contains:

• Purified water
• Propylene glycol
• Xylitol
• Methylparaben
• Propylparaben
• Flavoring agents
• FD&C Yellow No. 6
• Sodium hydroxide (pH adjustment)

The chemical name of emtricitabine is 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one, with the molecular formula C₈H₁₀FN₃O₃S and a molecular weight of 247.25 g/mol. It is a white to off-white crystalline powder that is soluble in water.